Publication:

Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations

Loading...
Thumbnail Image

Date

2017

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

John Wiley and Sons Inc.
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Ajore, R., D. Raiser, M. McConkey, M. Jöud, B. Boidol, B. Mar, G. Saksena, et al. 2017. “Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations.” EMBO Molecular Medicine 9 (4): 498-507. doi:10.15252/emmm.201606660. http://dx.doi.org/10.15252/emmm.201606660.

Abstract

Abstract Heterozygous inactivating mutations in ribosomal protein genes (RPGs) are associated with hematopoietic and developmental abnormalities, activation of p53, and altered risk of cancer in humans and model organisms. Here we performed a large‐scale analysis of cancer genome data to examine the frequency and selective pressure of RPG lesions across human cancers. We found that hemizygous RPG deletions are common, occurring in about 43% of 10,744 cancer specimens and cell lines. Consistent with p53‐dependent negative selection, such lesions are underrepresented in TP53‐intact tumors (P ≪ 10−10), and shRNA‐mediated knockdown of RPGs activated p53 in TP53‐wild‐type cells. In contrast, we did not see negative selection of RPG deletions in TP53‐mutant tumors. RPGs are conserved with respect to homozygous deletions, and shRNA screening data from 174 cell lines demonstrate that further suppression of hemizygously deleted RPGs inhibits cell growth. Our results establish RPG haploinsufficiency as a strikingly common vulnerability of human cancers that associates with TP53 mutations and could be targetable therapeutically.

Description

Research Data

Keywords

cancer, ribosomal gene haploinsufficiency, ribosome function, Cancer, Genetics, Gene Therapy & Genetic Disease

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories